A team of medical and veterinary researchers at the University of California – Davis examined the efficacy and immunologic effects of a novel triple therapy consisting of local radiotherapy, intratumoral CpG oligodeoxynucleotides (CpG ODN), and systemic indolamine-2,3-dioxygenase (IDO) blockade in mouse models and dog clinical trials. The addition of IDO blockage to radiotherapy + CpG decreased IDO activity, reduced tumor growth and reduced immunosuppressive factors.
- Arta Monjazeb, MD, PhD
- Michael Kent, DVM, PhD
Three key benefits to the findings
- Results suggested that IDO maintains immune suppression in tumors after therapy and IDO blockade promotes a local anti-tumor immune response with systemic consequences
- Demonstrated that combinatorial strategies designed to minimize overlapping toxicity can be safe and effective
- Results provided strong rationale for clinical translation of the triple-therapy strategy to substantially improve the already documented efficacy of radiotherapy + CpG